ALKS Alkermes plc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALKS

Price (delayed)

$24.26

Market cap

$4.05B

P/E Ratio

11.34

Dividend/share

N/A

EPS

$2.14

Enterprise value

$3.97B

Alkermes plc is a biopharmaceutical company that focuses on central nervous system diseases such as such as schizophrenia, depression, addiction and multiple sclerosis. The company was founded in 1987 by ...

Highlights
Alkermes's net income has soared by 66% from the previous quarter
The EPS has soared by 66% since the previous quarter
ALKS's quick ratio is up by 18% year-on-year but it is down by 13% since the previous quarter
The company's equity rose by 15% YoY but it fell by 11% QoQ
Sector: Healthcare
Industry: Biotechnology
Peers: BMY JNJ PFE TEVA

Key stats

What are the main financial stats of ALKS
Market
Shares outstanding
167.08M
Market cap
$4.05B
Enterprise value
$3.97B
Valuations
Price to earnings (P/E)
11.34
Price to book (P/B)
3.37
Price to sales (P/S)
2.42
EV/EBIT
14.11
EV/EBITDA
11.14
EV/Sales
2.39
Earnings
Revenue
$1.66B
EBIT
$281.15M
EBITDA
$356.08M
Free cash flow
$353.66M
Per share
EPS
$2.14
Free cash flow per share
$2.13
Book value per share
$7.21
Revenue per share
$10.01
TBVPS
$12.34
Balance sheet
Total assets
$2.14B
Total liabilities
$933.54M
Debt
$372.19M
Equity
$1.2B
Working capital
$965.29M
Liquidity
Debt to equity
0.31
Current ratio
2.86
Quick ratio
2.13
Net debt/EBITDA
-0.24
Margins
EBITDA margin
21.4%
Gross margin
84.8%
Net margin
21.4%
Operating margin
24.9%
Efficiency
Return on assets
16.7%
Return on equity
29.4%
Return on invested capital
20.3%
Return on capital employed
17.4%
Return on sales
16.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALKS stock price

How has the Alkermes stock price performed over time
Intraday
0.79%
1 week
2.06%
1 month
-11.1%
1 year
-17.43%
YTD
-12.55%
QTD
-10.38%

Financial performance

How have Alkermes's revenue and profit performed over time
Revenue
$1.66B
Gross profit
$1.41B
Operating income
$414.12M
Net income
$355.76M
Gross margin
84.8%
Net margin
21.4%
Alkermes's net income has soared by 66% from the previous quarter
The net margin has soared by 59% from the previous quarter
Alkermes's gross profit has soared by 58% YoY and by 4.2% from the previous quarter
The revenue has grown by 50% YoY and by 4.6% from the previous quarter

Growth

What is Alkermes's growth rate over time

Valuation

What is Alkermes stock price valuation
ALKS P/E details
P/E
11.34
P/B
3.37
P/S
2.42
EV/EBIT
14.11
EV/EBITDA
11.14
EV/Sales
2.39
The EPS has soared by 66% since the previous quarter
The P/B is 16% lower than the last 4 quarters average of 4.0 and 3.7% lower than the 5-year quarterly average of 3.5
The company's equity rose by 15% YoY but it fell by 11% QoQ
The revenue has grown by 50% YoY and by 4.6% from the previous quarter
ALKS's P/S is 29% below its last 4 quarters average of 3.4 and 24% below its 5-year quarterly average of 3.2

Efficiency

How efficient is Alkermes business performance
The ROA has soared by 62% QoQ
The return on equity has surged by 61% since the previous quarter
The ROIC has increased by 12% from the previous quarter
The ROS is up by 8% since the previous quarter

Dividends

What is ALKS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALKS.

Financial health

How did Alkermes financials performed over time
Alkermes's total assets is 129% higher than its total liabilities
The current ratio has grown by 26% YoY
ALKS's quick ratio is up by 18% year-on-year but it is down by 13% since the previous quarter
The debt is 69% less than the equity
The company's equity rose by 15% YoY but it fell by 11% QoQ
The debt to equity is down by 14% YoY but it is up by 11% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.